Glycotest™ Strengthens its Intellectual Property Reach by Expanding its United States, European and Australian Patent Portfolio

 

London, UK – 07 July 2017 NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that a European patent exclusively licensed to one of its portfolio companies, Glycotest, has been granted.  In addition, United States and Australian patents have been allowed.  These patents will significantly extend protection for Glycotest’s core technology for early detection of life threatening liver disease.

These patents expand the portfolio of six previously granted patents (three US and three ex-US patents) to strengthen protection of Glycotest’s biomarker and assay technology. Glycotest now holds patents in the US, Europe, Japan and Australia covering the use of over 50 unique glycoprotein biomarkers and related assay technology for the diagnosis of liver cancers and other liver diseases. 

As announced on 26 June 2017, the Company is aiming to close a Series A round within the second half of 2017.

NetScientific holds an 87.5% stake (67% on a fully diluted basis) in Glycotest. 

Glycotest’s lead product, HCC Panel, continues to significantly outperform the current dominant blood test (AFP) in separate 208 and 127 patient head-to-head clinical studies.

“We are very pleased to announce international strengthening of the IP landscape controlled by Glycotest in the field of liver diagnostics. The patents provide the foundation for future value enhancement and represent a critical step on Glycotest’s road to commercialisation. We look forward to further clinical validation of the Glycotest platform in H2 2017.”

Francois R. Martelet

NetScientific’s Chief Executive Officer and Chairman of Glycotest

The full text of the announcement from Glycotest can be found below.

 

For more information please contact:

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800

info@netscientific.net

 

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson /

Chris Welsh / Laura Thornton

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison

Tel: +44 (0) 20 7710 7600

 

Glycotest Inc.

Lawrence Cohen

Office: +1 646 722 4339

larry.cohen@glycotest.com

 

About NetScientific:

NetScientific is an IP commercialisation group focused on healthcare with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

Glycotest™ Intellectual Property Portfolio Expanded by United Sates, European and Australian Patents

New York, NY-July 07, 2017-Glycotest, Inc. announced today that a European patent has been granted and additional United States and Australian patents have been allowed.  Together these patents will extend protection of the Company’s core technology for early detection of life threatening liver disease.

Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis.  The Company’s mission is to reduce mortality and increase survival for the growing population at risk from serious liver diseases.  Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry. 

The granted European and allowed United States and Australian patents announced today join six other patents previously granted in the United States, Japan and Australia which have been licensed exclusively and on a worldwide basis to Glycotest by Drexel University College of Medicine and the Blumberg Institute of the Hepatitis B Foundation, both in the Philadelphia area.  These patents cover the use of over 50 unique glycoprotein biomarkers as well as related assay technology for the diagnosis of liver cancers and other liver diseases.  Together the granted patents and the additional pending applications protect Glycotest’s proprietary liver disease diagnostic platform. 

Commenting on these developments, Glycotest’s Chief Executive Officer Lawrence Cohen said, “The Glycotest patent portfolio is expanding in both the breadth of our technology protection and the jurisdictions in which we have granted patents.  We anticipate continued good news regarding our intellectual property portfolio which we expect to form the basis of a strong position in the liver disease diagnostics space.”

 

– Ends –

 

About Glycotest, Inc.

Glycotest is a private liver disease diagnostics company commercializing novel clinical laboratory testing services for patients at risk for liver cancers and fibrosis-cirrhosis. The Company was founded in 2012 on proprietary technology that originated at the Philadelphia area institutions Baruch S. Blumberg Institute and Drexel University College of Medicine.  Learn more at www.glycotest.com.


Back to previous page